Synthesis and characterization of heavy metal-based hydroxyapatite for batch adsorption of turquoise blue dye: equilibrium, kinetic, and thermodynamic studies

In this study, different metal hydroxyapatite (HAP) nanoparticles were synthesized at a laboratory scale. All the methods used were very economical because all reagents used in this work were cheap and easily available in laboratories. The synthesized products were characterized by X-ray diffractometer (XRD), Brunauer–Emmett–Teller and Barrett–Joyner–Halenda, scanning electron microscopy, and Fourier transform infrared spectroscopy analysis to confirm the synthesis of respective products by ensuring the presence of phosphate and hydroxyl functional groups. These metal HAP nanoparticles were applied in water treatment applications as adsorbents for the elimination of turquoise blue dye from the aqueous solution. Batch experiments were performed, and all effective parameters were optimized. Their optimized values were as follows: pH = 8, dosage of adsorbent = 0.05 g, contact time = 75 min, temperature = 30 °C, and dye concentration = 75 ppm. The order of adsorption capacity of four different metal HAP products was determined as calcium-HAP (Ca-HAP) > lead-HAP (Pb-HAP) > strontium-HAP (Sr-HAP) > barium-HAP (Ba-HAP). Ca-HAP, Ba-HAP, Sr-HAP, and Pb-HAP have the highest concentration of 0.5 N, giving 54–69.29% desorption. Moreover, the effect of surfactants and electrolytes was also studied. Langmuir isotherm and pseudo-second-order kinetic model were best fitted for turquoise blue dye adsorption. The reaction was exothermic and spontaneous in nature. HIGHLIGHTS Synthesis of nano metal hydroxyapatite (HAP) by the wet precipitation method.; Applications of HAP as a useful material in turquoise blue dye adsorption.; The order of adsorption capacity of four different metal HAP products was determined as Ca-HAP > Pb-HAP > Sr-HAP > Ba-HAP.; The Langmuir model and pseudo-second-order kinetic model were best fitted.

Actas Pink-2B dye removal in biochar nanocomposites augmented vertical flow constructed wetland (VF-CWs)

Industries generate hazardous dye wastewater, posing significant threats to public health and the environment. Removing dyes before discharge is crucial. The ongoing study primarily focused on synthesizing, applying, and understanding the mechanism of green nano-biochar composites. These composites, including zinc oxide/biochar, copper oxide/biochar, magnesium oxide/biochar, and manganese oxide/biochar, are designed to effectively remove Actas Pink-2B (Direct Red-31) in conjunction with constructed wetlands. Constructed wetland maintained pH 6.0–7.9. At the 10th week, the copper oxide/biochar treatment demonstrated the highest removal efficiency of total suspended solids (72%), dissolved oxygen (7.2 mg/L), and total dissolved solids (79.90%), followed by other biochar composites. The maximum removal efficiency for chemical oxygen demand (COD) and color was observed at a retention time of 60 days. The electrical conductivity also followed the same order, with a decrease observed up to the 8th week before becoming constant. A comprehensive statistical analysis was conducted, encompassing various techniques including variance analysis, regression analysis, correlation analysis, and principal component analysis. The rate of color and COD removal followed a second-order and first-order kinetics, respectively. A significant negative relationship was observed between dissolved oxygen and COD. The study indicates that employing biochar composites in constructed wetlands improves textile dye removal efficiency. The novelty of this study is the selection of Cymbopogon as a proper plant for phytoremediation of dye along with green metal oxide coated biochar. These were selected due to their good ability to remove organic pollutant. This study demonstrates the uptake and degradation processes of persistent dye in constructed wetland.</p

Epidemiology of <i>Streptococcus pneumoniae</i> Serotypes in Jordan Amongst Children Younger than the Age of 5: A National Cross-Sectional Study

Introduction: Streptococcus pneumoniae infections are a major cause of mortality and morbidity worldwide. In Jordan, pneumococcal conjugate vaccines (PCVs) are not included in the national vaccination program. Due to the current availability of several PCVs, including PCV-10, PCV-13, and PCV-15, along with PCV-20, currently undergoing pediatric approvals globally, the decision to introduce PCVs and their selection should be based on valid local data on the common serotypes of Streptococcus pneumoniae. Methods: This cross-sectional study aimed to identify the frequency of serotypes of Streptococcus pneumoniae in children aged below 5 years hospitalized with invasive pneumococcal diseases (IPDs), including pneumonia, septicemia, and meningitis, during the study’s duration in representative areas of Jordan. Serotyping for culture-positive cases was based on the capsular reaction test, known as the Quellung reaction. qPCR was conducted on the blood samples of patients with lobar pneumonia identified via X-ray or on cerebrospinal fluid for those with a positive latex agglutination test for Streptococcus pneumoniae. Results: This study was based on the analysis of the serotypes of 1015 Streptococcus pneumoniae cases among children younger than the age of 5: 1006 cases with pneumonia, 6 cases with meningitis, and 3 cases with septicemia. Only 23 culture-positive cases were identified in comparison to 992 lobar pneumonia cases, which were PCR-positive but culture-negative, with a PCR positivity rate of 92%. Serotypes 6B, 6A, 14, and 19F were the most common serotypes identified in this study, with prevalence rates of 16.45%, 13.60%, 12.12%, and 8.18%, respectively. PCV-10, PCV-13, PCV-15, and PCV-20 coverage rates were 45.32%, 61.87%, 64.14%, and 68.47%, respectively. Discussion: To the best of our knowledge, this is the largest prospective study from the Middle East and one of the largest studies worldwide showing the serotypes of Streptococcus pneumoniae. It reveals the urgency for the introduction of a PCV vaccination in Jordan, utilizing recently developed vaccines with a broader serotype coverage

Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries

© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 licenseBackground: 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality. Methods: This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov, NCT03471494. Findings: Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications. Interpretation: Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications. Funding: National Institute for Health Research Global Health Research Unit

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. Methods: A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Findings: Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Interpretation: Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. Funding: National Institute for Health and Care Research